Citius Pharmaceuticals Inc. Common (CTXR) Dividend History

Company News

• Citius Oncology Announces Pricing of $9.0 Million Public Offering

  Citius Oncology priced a public offering of 6,818,182 shares and warrants at $1.32 per share, expecting to raise approximately $9.0 million to support LYMPHIR commercialization and general corporate purposes.

  Benzinga

  Featured Companies: CTOR
• After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)

  The heavy selling pressure might have exhausted for Citius Pharmaceuticals, Inc. (CTXR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

  Zacks Investment Research
• Trading Penny Stocks on April 6th, MOBQ Stock Pushes Up

  Here's what you need to know about trading penny stocks on April 6th The post Trading Penny Stocks on April 6th, MOBQ Stock Pushes Up appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: SBFM TLRY
• Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

  With cash balance of $115.7 million, Citius will likely incur a loss in the E7777 transaction. It requires an upfront payment of $40 million and milestone payments of up to $110 million.

  Seeking Alpha
• Could Citius Pharmaceuticals Be a Millionaire-Maker Stock?

  A lot would have to go right for this biotech to make investors rich.

  The Motley Fool